Invesco’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.6M Buy
886,476
+254,787
+40% +$12.1M ﹤0.01% 1239
2025
Q4
$32.1M Buy
631,689
+107,695
+21% +$5.51M ﹤0.01% 1245
2025
Q3
$29.1M Buy
523,994
+104,303
+25% +$6.11M ﹤0.01% 1294
2025
Q2
$29M Buy
419,691
+87,467
+26% +$5.95M ﹤0.01% 1277
2025
Q1
$23.1M Sell
332,224
-16,984
-5% -$1.4M ﹤0.01% 1360
2024
Q4
$30M Sell
349,208
-171,244
-33% -$18.5M 0.01% 1293
2024
Q3
$62M Sell
520,452
-300,689
-37% -$40.1M 0.01% 953
2024
Q2
$117M Sell
821,141
-32,512
-4% -$4.31M 0.02% 726
2024
Q1
$110M Buy
853,653
+97,147
+13% +$11.6M 0.02% 763
2023
Q4
$78.3M Buy
756,506
+181,839
+32% +$18M 0.02% 829
2023
Q3
$52.3M Sell
574,667
-51
-0% -$4.49K 0.01% 935
2023
Q2
$46.5M Buy
574,718
+131,348
+30% +$10.7M 0.01% 979
2023
Q1
$35.3M Buy
443,370
+71,302
+19% +$5.06M 0.01% 1097
2022
Q4
$25.2M Sell
372,068
-53,740
-13% -$3.15M 0.01% 1262
2022
Q3
$21.2M Sell
425,808
-144,628
-25% -$7.75M 0.01% 1277
2022
Q2
$31.8M Sell
570,436
-896,722
-61% -$49.8M 0.01% 1113
2022
Q1
$81.5M Buy
1,467,158
+610,676
+71% +$31.3M 0.02% 843
2021
Q4
$48M Buy
856,482
+239,308
+39% +$13M 0.01% 1063
2021
Q3
$29.6M Sell
617,174
-28,486
-4% -$1.38M 0.01% 1314
2021
Q2
$27M Sell
645,660
-11,738
-2% -$455K 0.01% 1414
2021
Q1
$22.2M Sell
657,398
-23,984
-4% -$854K 0.01% 1468
2020
Q4
$23.8M Sell
681,382
-29,404
-4% -$1.02M 0.01% 1342
2020
Q3
$24.7M Buy
710,786
+202,278
+40% +$6.74M 0.01% 1206
2020
Q2
$16.6M Buy
508,508
+188,838
+59% +$6.03M 0.01% 1355
2020
Q1
$9.62M Buy
319,670
+126,874
+66% +$3.78M ﹤0.01% 1544
2019
Q4
$5.58M Sell
192,796
-42,800
-18% -$1.19M ﹤0.01% 2103
2019
Q3
$6.09M Sell
235,596
-52,066
-18% -$1.32M ﹤0.01% 2018
2019
Q2
$7.34M Sell
287,662
-34,132
-11% -$844K ﹤0.01% 1949
2019
Q1
$8.42M Sell
321,794
-61,326
-16% -$1.51M ﹤0.01% 1681
2018
Q4
$8.83M Sell
383,120
-13,216
-3% -$294K ﹤0.01% 1595
2018
Q3
$9.34M Sell
396,336
-2,250
-0.6% -$54.9K ﹤0.01% 1749
2018
Q2
$9.19M Sell
398,586
-47,984
-11% -$1.14M ﹤0.01% 1728
2018
Q1
$11M Sell
446,570
-356,442
-44% -$9.36M ﹤0.01% 1476
2017
Q4
$21.5M Sell
803,012
-108,512
-12% -$2.76M 0.01% 1176
2017
Q3
$21.9M Sell
911,524
-69,448
-7% -$1.57M 0.01% 1151
2017
Q2
$21M Sell
980,972
-874,400
-47% -$17.6M 0.01% 1169
2017
Q1
$31.8M Sell
1,855,372
-386,090
-17% -$6.72M 0.01% 998
2016
Q4
$40.2M Buy
2,241,462
+227,252
+11% +$4.12M 0.01% 886
2016
Q3
$41.9M Sell
2,014,210
-312,670
-13% -$7.75M 0.01% 843
2016
Q2
$62.6M Sell
2,326,880
-132,004
-5% -$3.62M 0.02% 656
2016
Q1
$66.6M Sell
2,458,884
-207,446
-8% -$5.56M 0.03% 612
2015
Q4
$77.4M Sell
2,666,330
-581,510
-18% -$16.1M 0.03% 605
2015
Q3
$88.1M Buy
3,247,840
+3,532
+0.1% +$100K 0.04% 520
2015
Q2
$88.8M Buy
3,244,308
+4,276
+0.1% +$120K 0.03% 558
2015
Q1
$86.5M Sell
3,240,032
-27,276
-0.8% -$628K 0.03% 570
2014
Q4
$69.1M Sell
3,267,308
-121,248
-4% -$2.71M 0.03% 656
2014
Q3
$80.7M Buy
3,388,556
+235,704
+7% +$5.42M 0.03% 577
2014
Q2
$72.8M Buy
3,152,852
+579,414
+23% +$12.8M 0.03% 631
2014
Q1
$58.7M Sell
2,573,438
-108,592
-4% -$2.31M 0.02% 710
2013
Q4
$49.6M Buy
2,682,030
+195,160
+8% +$3.4M 0.02% 802
2013
Q3
$42.1M Buy
2,486,870
+229,940
+10% +$3.87M 0.02% 847
2013
Q2
$35M Buy
+2,256,930
New +$37.6M 0.02% 871

Other funds holding NVO

Invesco's NVO Position: Q1 2026 in Review

Invesco increased its Novo Nordisk (NVO) stake by 40% in Q1 2026, buying an estimated $12.1M and bringing the position to 886,476 shares worth $32.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1239.

Invesco first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $117M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Invesco held 886,476 shares of Novo Nordisk worth $32.6M as of Q1 2026.
  • Invesco bought 254,787 Novo Nordisk shares in Q1 2026, an estimated $12.1M.
  • Novo Nordisk made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1239 holding.
  • Invesco first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Invesco's Novo Nordisk position peaked at $117M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.